ARMR Sciences, Inc.
ARMR Sciences, Inc. is a biotechnology company dedicated to ending the fentanyl crisis and defending against synthetic drug threats through American innovation. The company is pioneering scalable, preventative immunotherapies to protect individuals before exposure to lethal synthetic drugs like fentanyl, moving beyond reactive treatments to address the root causes of overdose deaths. ARMR's technology is supported by foundational licenses from the Department of Defense and aligns with federal health and defense agencies. The multidisciplinary team brings significant experience from leading institutions and companies such as MindMed, iBio, Ridgeback Biotherapeutics, Scripps Research, Boston Children’s Hospital, Harvard Medical School, and more. United in their vision to save lives, ARMR is committed to providing lasting protection and solving the overdose crisis for millions in need.
ARMR Sciences, Inc. is currently seeking investment
ARMR Sciences, Inc. is seeking a series-b investment in the range of 20m-50m
What We Do
A preventative immunotherapy in development, designed to provide scalable, long-lasting protection against synthetic opioids like fentanyl (ARMR-100), carfentanil(ARMR-100), xylazine, nitazenes, and medetomidine. The vaccine aims to work like a tetanus shot, arming the body to produce a protective immune response that neutralizes lethal synthetic drugs before they can cause harm. Initial administration is by injection, with a nasal spray & sublingual formulation under development. All claims are based on preclinical animal research and have not yet been evaluated in humans.
ARMR Sciences may provide physician-requested expanded access to its investigational medicines in the U.S. and other countries where it intends to submit an application for marketing authorization. This is considered in specific circumstances when no alternative therapies are available and there is adequate clinical evidence of a positive benefit to risk profile.
Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Regenerative Medicine
Digital Health Technologies
Key People
Chief Scientific Officer
News & Updates
ARMR technology is already backed by the Department of Defense through its foundational license, supporting the development of preventative immunotherapies against synthetic drug threats.
Collin Gage, CEO of ARMR Sciences, discusses the company's focus on safety and transparency in their mission to end the fentanyl crisis.
Bloomberg features ARMR Sciences' efforts to develop a fentanyl vaccine that could help solve opioid drug deaths and overdoses.
Bloomberg covers ARMR Sciences' startup efforts to chemically prevent highs and overdoses from fentanyl with their vaccine.
CBS reports on ARMR Sciences' vaccine for fentanyl overdose as it heads to clinical trial, highlighting its potential to help end fentanyl deaths.
DailyMail discusses ARMR Sciences' groundbreaking fentanyl vaccine and its potential to curb the ongoing epidemic.